Medicare Enrolled
Dr. Paul Dodd, MD
Hematology · Ormond Beach, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Dodd from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dodd? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Dodd
Dr. Paul Dodd is a hematology in Ormond Beach, FL, with 20 years in practice. Based on federal Medicare data, Dr. Dodd performed 354,016 Medicare services across 6,080 unique beneficiaries.
Between the years covered by Open Payments, Dr. Dodd received a total of $6,632 from 63 pharmaceutical and/or device companies across 385 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Dodd is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 5% volume in FL$ $6,632 industry payments
Medicare Practice Summary
Medicare Utilization ↗354,016
Medicare services
Top 5% in FL for hematology
6,080
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~17,701 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 118,830 | $0 | $4 |
| Nivolumab injection (Opdivo) | 37,220 | $24 | $72 |
| Pembrolizumab injection (Keytruda) | 26,400 | $43 | $137 |
| Filgrastim injection (Zarxio) for white blood cells | 24,960 | $0 | $2 |
| Anti-nausea injection (aprepitant) | 22,880 | $1 | $5 |
| Iron infusion (Injectafer) | 21,750 | $1 | $3 |
| Filgrastim injection (Nivestym) for white blood cells | 14,820 | $0 | $1 |
| Epoetin alfa injection (Procrit) for anemia | 14,220 | $6 | $23 |
| Paclitaxel chemotherapy injection | 12,366 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 10,620 | $18 | $51 |
| Dexamethasone injection (steroid) | 5,507 | $0 | $3 |
| Injection, degarelix, 1 mg | 5,360 | $3 | $10 |
| Iron infusion (Monoferric) | 4,700 | $17 | $57 |
| Complete blood count (CBC) with differential | 4,094 | $8 | $29 |
| Blood draw (venipuncture) | 3,830 | $8 | $9 |
| Injection, eflapegrastim-xnst, 0.1 mg | 3,432 | $26 | $116 |
| Injection, rituximab, 10 mg | 2,880 | $64 | $232 |
| Anti-nausea injection (ondansetron/Zofran) | 2,432 | $0 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,160 | $1 | $28 |
| Office visit, established patient (30-39 min) | 1,825 | $96 | $339 |
| Drug injection, under skin or into muscle | 1,436 | $10 | $69 |
| Injection, leucovorin calcium, per 50 mg | 988 | $3 | $12 |
| Administration of chemotherapy into vein, 1 hour or less | 906 | $97 | $378 |
| Injection of additional new drug or substance into vein | 835 | $12 | $61 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 834 | $3 | $205 |
| Office visit, established patient (20-29 min) | 632 | $64 | $239 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 609 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 564 | $48 | $189 |
| Injection, fluorouracil, 500 mg | 562 | $2 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 421 | $22 | $84 |
| Injection, carboplatin, 50 mg | 413 | $2 | $41 |
| Administration of chemotherapy into vein, each additional hour | 378 | $21 | $79 |
| Injection, magnesium sulfate, per 500 mg | 376 | $1 | $2 |
| Injection, cisplatin, powder or solution, 10 mg | 343 | $2 | $13 |
| Injection, potassium chloride, per 2 meq | 290 | $0 | $4 |
| Injection, diphenhydramine hcl, up to 50 mg | 288 | $1 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 272 | $15 | $56 |
| Administration of additional new drug or substance into vein, 1 hour or less | 265 | $49 | $178 |
| Injection of drug or substance into vein | 253 | $27 | $156 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 252 | $134 | $562 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 212 | $24 | $89 |
| Injection, zoledronic acid, 1 mg | 196 | $7 | $69 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 190 | $54 | $206 |
| Infusion, normal saline solution , 1000 cc | 189 | $2 | $7 |
| Hospital follow-up visit, moderate complexity | 187 | $62 | $197 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 186 | $17 | $59 |
| Infusion into a vein for hydration, each additional hour | 170 | $9 | $42 |
| New patient office visit (45-59 min) | 141 | $120 | $453 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 133 | $4 | $15 |
| Prothrombin time test (blood clotting) | 119 | $4 | $15 |
| Initial hospital admission, high complexity | 116 | $136 | $556 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 111 | $3 | $11 |
| Administration of additional new drug or substance into vein using push technique | 108 | $42 | $170 |
| Office visit, established patient, complex (40-54 min) | 101 | $139 | $474 |
| Automated urinalysis | 98 | $2 | $8 |
| Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg | 93 | $305 | $1,210 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 84 | $129 | $637 |
| New patient office visit, complex (60-74 min) | 77 | $163 | $585 |
| Infusion into a vein for hydration, 31-60 minutes | 76 | $25 | $156 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 60 | $15 | $56 |
| Red blood count, automated test | 43 | $4 | $10 |
| Drawing of blood for a medical problem | 40 | $65 | $277 |
| Administration of chemotherapy into vein using push technique | 35 | $74 | $303 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 34 | $1 | $7 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 14 | $135 | $467 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
41.6% high complexity
55.0% medium
3.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,632
Total received (2018-2024)
Avg $947/year across 7 years
Bottom 47% in FL for hematology
63
Companies
385
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,933 (89.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$700 (10.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,324
2023$1,426
2022$1,059
2021$178
2020$212
2019$1,040
2018$1,392
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$959
PFIZER INC.
$640
Janssen Biotech, Inc.
$569
Genentech USA, Inc.
$492
Merck Sharp & Dohme Corporation
$261
Celgene Corporation
$245
E.R. Squibb & Sons, L.L.C.
$217
Astellas Pharma US Inc
$205
ARRAY BIOPHARMA INC
$194
Gilead Sciences, Inc.
$174
Incyte Corporation
$166
Pharmacyclics LLC, An AbbVie Company
$152
Amgen Inc.
$147
Exelixis Inc.
$146
Kite Pharma, Inc.
$124
SANOFI-AVENTIS U.S. LLC
$95
ABBVIE INC.
$93
Lilly USA, LLC
$81
G1 Therapeutics, Inc.
$78
EMD Serono, Inc.
$72
Regeneron Healthcare Solutions, Inc.
$71
Bayer HealthCare Pharmaceuticals Inc.
$70
Ipsen Biopharmaceuticals, Inc
$67
Eisai Inc.
$65
MEDIVATION FIELD SOLUTIONS LLC
$62
AstraZeneca Pharmaceuticals LP
$59
Merck Sharp & Dohme LLC
$56
GENZYME CORPORATION
$54
Secura Bio, Inc.
$54
GlaxoSmithKline, LLC.
$53
Alnylam Pharmaceuticals Inc.
$53
Pharmacyclics LLC, an AbbVie Company
$51
Alexion Pharmaceuticals, Inc.
$50
CTI BioPharma Corp.
$47
PharmaEssentia USA Corporation
$43
Rigel Pharmaceuticals, Inc.
$41
Seagen Inc.
$40
Seattle Genetics, Inc.
$39
ADC Therapeutics America, Inc.
$39
NanoString Technologies, Inc.
$36
Octapharma USA, Inc.
$35
Janssen Pharmaceuticals, Inc
$33
Aurobindo Pharma USA, Inc.
$32
Array BioPharma Inc.
$31
Foundation Medicine, Inc.
$27
Horizon Therapeutics plc
$26
AbbVie Inc.
$23
Coherus Biosciences Inc.
$23
Boehringer Ingelheim Pharmaceuticals, Inc.
$22
TerSera Therapeutics LLC
$22
SOBI, INC
$21
Sysmex Inostics Inc
$21
Karyopharm Therapeutics Inc.
$20
Pharmacosmos Therapeutics Inc.
$19
Helsinn Therapeutics (U.S.), Inc.
$17
Lexicon Pharmaceuticals, Inc.
$17
Daiichi Sankyo Inc.
$15
Taiho Oncology, Inc.
$15
Aveo Pharmaceuticals, Inc.
$14
Otsuka America Pharmaceutical, Inc.
$14
TAIHO ONCOLOGY, INC.
$13
PUMA BIOTECHNOLOGY, INC.
$12
Veracyte, Inc.
$4
Top 3 companies account for 32.7% of total payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · Alecensa · Aliqopa · Avastin · BAVENCIO · BENLYSTA · BESREMI · BOSULIF · BRAFTOVI · Bavencio · Braftovi · CABOMETYX · COPIKTRA · COSELA · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELAHERE · ELIQUIS · EMEND · ENJAYMO · ERBITUX · ERLEADA · Erleada · FARYDAK · FOTIVDA · GAZYVA · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · INFLECTRA · INJECTAFER · INLYTA · INQOVI · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRYSTEXXA · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MVASI · NERLYNX · Nexavar · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONPATTRO · OPDIVO · OPDUALAG · Onivyde · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROSIGNA ASSAY · Padcev · Perjeta · Polivy · Pomalyst · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SPRYCEL · SUTENT · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TUKYSA · Tavalisse · Tecentriq · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XARELTO · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · Yescarta · ZEJULA · Zevalin · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (90%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
8
Per 100K population
1.4
County median income
$66,581
Nearest hospital
ADVENTHEALTH DAYTONA BEACH
6.9 mi
6.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Dodd is a mixed practice specialist, with above-average Medicare volume (top 5% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Dodd experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Dodd performed 118,830 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Dodd receive payments from pharmaceutical companies?
Yes. Dr. Dodd received a total of $6,632 from 63 companies across 385 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dodd's costs compare to other hematologys in Ormond Beach?
Dr. Dodd's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dodd) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Ormond Beach
Browse hematologys in Ormond Beach ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology